A

pair of lawmakers wants the US Food and Drug Administration to explain its rationale for approving a decades-old drug to treat a rare disease that has caused controversy after the manufacturer, Marathon Pharmaceuticals, set a surprisingly high price of $89,000 a year.

In particular, the lawmakers are upset that the agency extended two coveted prizes — orphan drug designation and a priority review voucher —that provide Marathon with seven years of marketing exclusivity and, potentially, extra cash even though the company did not invent the drug.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • While I respect the Senator’s right to quote ‘more effective, safe and more affordable,’ I have heard FDA say that the price/ economic factors around a drug are not within their purview to review. As I know the FD&C Act, the criteria are ‘Pure, Safe and Effective.’ The economic$ are not included.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X